Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 7Phase 1/2 5Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 3Lymphoma 3Hodgkin Disease 3Lymphoma, T-Cell 2Hematologic Diseases 2Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Crizotinib 2Vindesine 1Vincristine 1Rituximab 1Radiation 1R-CHOP protocol 1Prednisolone 1Methotrexate 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Doxorubicin 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, Large-Cell, Anaplastic × Brentuximab Vedotin × Clear all
NCT01909934 2025-09-19

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Takeda

Phase 4 Completed
50 enrolled 22 charts
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡